N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

Background:Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. Methods:In a nested case–control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression. Results:At baseline median NT-proBNP [interquartile range (IQR)] was 48.1 (18.5, 112.9) pg/ml in patients who developed a CVD event and 25.7 (12.4, 50.2) pg/ml in controls. The unadjusted OR for the highest versus the lowest quartile was 3.7 [95% confidence interval (CI) 2.1–6.5, P < 0.0001]. After adjustment for baseline covariates and CVD risk factors, OR was 2.8 (95% CI 1.4–5.6, P = 0.003); with additional adjustment for IL-6, high-sensitivity C-reactive protein and D-dimer, OR was 2.3 (95% CI 1.1–4.9, P = 0.02). Conclusions:Higher levels of NT-proBNP are associated with increased risk of CVD in HIV patients after considering established CVD risk factors and markers for inflammation and thrombosis.

[1]  A. Gori,et al.  Markers of hypercoagulability and inflammation predict mortality in patients with heart failure , 2006, Journal of thrombosis and haemostasis : JTH.

[2]  K. Anastos,et al.  Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. , 2009, AIDS Research and Human Retroviruses.

[3]  A. Phillips,et al.  Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. , 2008, Annals of internal medicine.

[4]  A. Maisel,et al.  B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department , 2009, Coronary artery disease.

[5]  J. Danesh,et al.  B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies , 2009, Circulation.

[6]  A. Mocroft,et al.  Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients , 2010, AIDS.

[7]  A. Jaffe,et al.  National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. , 2008, Circulation.

[8]  T. Yokoyama,et al.  Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. , 2002, Journal of molecular and cellular cardiology.

[9]  J. Brenchley,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.

[10]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[11]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[12]  N. Nikolaou,et al.  Brain natriuretic peptide increases in septic patients without severe sepsis or shock. , 2007, European journal of internal medicine.

[13]  Pedro Lozano.  Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.

[14]  G. Mensah,et al.  Screening and assessment of coronary heart disease in HIV-infected patients. , 2008, Circulation.

[15]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[16]  B. Hesse,et al.  Right and left cardiac function in HIV‐infected patients investigated using radionuclide ventriculography and brain natriuretic peptide: a 5‐year follow‐up study , 2008, HIV medicine.

[17]  P. Sax.  Assessing risk for cardiovascular disease in patients with human immunodeficiency virus: Why it matters. , 2010, Circulation.

[18]  A. Phillips,et al.  Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial , 2008, Antiviral therapy.

[19]  C. Latkin,et al.  Correlates of Lending Needles/Syringes Among HIV-Seropositive Injection Drug Users , 2007, Journal of acquired immune deficiency syndromes.

[20]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[21]  A. Maisel,et al.  State-of-the-Art PaperNatriuretic Peptides , 2007 .

[22]  R. Erbel,et al.  Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART). , 2005, European journal of medical research.

[23]  Jeffrey N. Martin,et al.  Impact of HIV Infection on Diastolic Function and Left Ventricular Mass , 2010, Circulation. Heart failure.

[24]  J. Struck,et al.  Plasma NT-proBNP increases in response to LPS administration in healthy men. , 2008, Journal of applied physiology.

[25]  A. D. de Bold,et al.  Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. , 2004, Journal of molecular and cellular cardiology.

[26]  D. Duprez,et al.  Untreated HIV Infection and Large and Small Artery Elasticity , 2009, Journal of Acquired Immune Deficiency Syndromes.

[27]  H. Sørensen,et al.  Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Hang Lee,et al.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. , 2007, The Journal of clinical endocrinology and metabolism.

[29]  C. Katlama,et al.  HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population , 2007, Journal of acquired immune deficiency syndromes.

[30]  Milton C Weinstein,et al.  The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.

[31]  G. Lamas,et al.  Brain natriuretic peptide and HIV-related cardiomyopathy. , 2002, The AIDS reader.

[32]  Y. Pinto,et al.  Amino-terminal pro-B-type natriuretic peptide testing in renal disease. , 2008, The American journal of cardiology.